iarjimphIARJIMPHIARJIMPH2709-331X10.47310/iarjimph.2024.v05i02.09Comparing Lisinopril and Telmisartan on Renal Function in Diabetes Type 2 and Hypertensive PatientsOsamahAbdullahHasanFadhelAbbasAl-hammamiAhmedMohammedAbdullahRasoolKhalidMohammedAnowarSuhadWaadPHD in Pharmacology, Kirkuk Health Directorate, Kirkuk, IraqAsst. Prof., Pharmacology, College of Medicine, University of Mosul, Iraq.BS Pharmacology, Alkitab University., Kirkuk, IraqBackground: Diabetes is a non-communicable and severe disease sometimes referred to as a "silent killer." Hypertension often occurs alongside renal issues, and both hurt the kidneys. They are a primary factor in the development of cardiovascular problems and immune and nervous system issues. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers play a role in the development of cardiovascular and renal problems in individuals with diabetes and hypertension. Aim: The study examines the impact of lisinopril versus telmisartan on creatinine, urea, and uric acid levels in newly diagnosed hypertensive diabetic patients. methodology: The study followed a randomized controlled comparative trial format for seven months. Forty-three patients were treated with lisinopril and 39 with telmisartan. All patients were using the medication glibenclamide. Forty-eight healthy individuals were selected as controls. Enzymatic, colorimetric, and uricase methods were utilized to test serum creatinine, urea, and uric acid. Results: Research findings indicate that diabetic patients undergoing treatment with Lisinopril experienced a notable reduction in blood creatinine levels. In contrast, individuals treated with telmisartan saw a considerable decline in serum urea levels but a significant rise in uric acid levels.  Conclusion: Lisinopril may be more effective than telmisartan in preserving renal function.